$ARDX earnings report

Q3 2026 total product revenue of $125.5 million, reflecting 19% growth year-over-year; IBSRELA Q3 2026 revenue growth of 23% year-over-year to $96.3 million. AlphAI read Ardelyx's Third Quarter 2026 filing as solid.

Third Quarter 2026

AlphAI · Earnings readARDX · Third Quarter 2026 · ended September 30, 2026

Q3 2026 total product revenue of $125.5 million, reflecting 19% growth year-over-year; IBSRELA Q3 2026 revenue growth of 23% year-over-year to $96.3 million.

✓Solid quarter

Total product revenue grew 19% year-over-year to $125.5 million, led by 23% IBSRELA growth, while the company reiterated 2026 revenue and operating-expense guidance and completed ACCEL enrollment ahead of schedule. The quarter still produced a net loss of $0.7 million and reflected higher R&D and SG&A spending.

Revenue
$128M
IBSRELA, Three Months Ended September 30, 2026
$96.3M
23% y/y
EPS · GAAP
$(0.00)
Full-year 2026 outlook
IBSRELA between $350 and $370 million; XPHOZAH between $110 and $120 million.

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total product sales, net, Three Months Ended September 30, 2026GAAP$125.5M–19%
Product supply revenue, Three Months Ended September 30, 2026GAAP$1.38M––
Licensing revenue, Three Months Ended September 30, 2026GAAP$216K––
Non-cash royalty revenue related to the sale of future royalties, Three Months Ended September 30, 2026GAAP$604K––
Total revenues, Three Months Ended September 30, 2026GAAP$127.7M––
Cost of sales, Three Months Ended September 30, 2026GAAP$4.54M––
Research and development, Three Months Ended September 30, 2026GAAP$25.20M––
Selling, general and administrative, Three Months Ended September 30, 2026GAAP$93.89M––
Total costs and operating expenses, Three Months Ended September 30, 2026GAAP$123.6M––
Income (loss) from operations, Three Months Ended September 30, 2026GAAP$4.02M––
Interest expense, Three Months Ended September 30, 2026GAAP−$5.88M––
Non-cash interest expense related to the sale of future royalties, Three Months Ended September 30, 2026GAAP−$1.50M––
Other income, net, Three Months Ended September 30, 2026GAAP$2.71M––
Loss before provision for income taxes, Three Months Ended September 30, 2026GAAP−$647K––
Provision for income taxes, Three Months Ended September 30, 2026GAAP$90K––
Net loss, Three Months Ended September 30, 2026GAAP−$737K––
Net loss per share of common stock - basic and diluted, Three Months Ended September 30, 2026GAAP$(0.00) per share––
Shares used in computing net loss per share - basic and diluted, Three Months Ended September 30, 2026GAAP250,007,187––
Total product sales, net, Nine Months Ended September 30, 2026GAAP$337.0M––
Product supply revenue, Nine Months Ended September 30, 2026GAAP$3.71M––
Licensing revenue, Nine Months Ended September 30, 2026GAAP$363K––
Non-cash royalty revenue related to the sale of future royalties, Nine Months Ended September 30, 2026GAAP$1.98M––
Total revenues, Nine Months Ended September 30, 2026GAAP$343.0M––
Cost of sales, Nine Months Ended September 30, 2026GAAP$15.11M––
Research and development, Nine Months Ended September 30, 2026GAAP$71.49M––
Selling, general and administrative, Nine Months Ended September 30, 2026GAAP$297.6M––
Total costs and operating expenses, Nine Months Ended September 30, 2026GAAP$384.2M––
Income (loss) from operations, Nine Months Ended September 30, 2026GAAP−$41.20M––
Interest expense, Nine Months Ended September 30, 2026GAAP−$16.44M––
Non-cash interest expense related to the sale of future royalties, Nine Months Ended September 30, 2026GAAP−$4.09M––
Other income, net, Nine Months Ended September 30, 2026GAAP$6.86M––
Loss before provision for income taxes, Nine Months Ended September 30, 2026GAAP−$54.85M––
Provision for income taxes, Nine Months Ended September 30, 2026GAAP$208K––
Net loss, Nine Months Ended September 30, 2026GAAP−$55.06M––
Net loss per share of common stock - basic and diluted, Nine Months Ended September 30, 2026GAAP$(0.22) per share––
Shares used in computing net loss per share - basic and diluted, Nine Months Ended September 30, 2026GAAP247,991,715––
Cash, cash equivalents and short-term investments, September 30, 2026GAAP$285.3M––
Cash and cash equivalents, September 30, 2026GAAP$46.32M––
Short-term investments, September 30, 2026GAAP$239.0M––
Accounts receivable, September 30, 2026GAAP$93.44M––
Inventory, September 30, 2026GAAP$157.6M––
Total assets, September 30, 2026GAAP$587.5M––
Long-term debt, September 30, 2026GAAP$252.4M––
Deferred royalty obligation related to the sale of future royalties, September 30, 2026GAAP$27.21M––
Total stockholders’ equity, September 30, 2026GAAP$164.0M––

Segments

SegmentRevenueq/qy/y
IBSRELA, Three Months Ended September 30, 2026The growth was driven by increases in total writers and total prescriptions.$96.3M–23%
XPHOZAH, Three Months Ended September 30, 2026Not specified.$29.2M–7%

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Full-year 2026 outlook

  • RevenueIBSRELA between $350 and $370 million; XPHOZAH between $110 and $120 million.
  • Operating expensesbelow $500 million
  • NoteIBSRELA long-term guidance of achieving $1 billion in annual revenue remains.
  • NoteThe Company is on track to announce topline data in the second half of 2027.

What drove it

  • Total product revenue growth was driven by increased demand.
  • IBSRELA growth was driven by increases in total writers and total prescriptions.
  • R&D expense increased primarily due to investments in the ACCEL Phase 3 trial for CIC.
  • SG&A expense increased due to deliberate investments to address access barriers and drive future adoption of IBSRELA.
  • Enrollment was completed ahead of schedule in the Phase 3 ACCEL trial evaluating tenapanor for CIC in adults.

Concerns

  • Net loss was $0.7 million for the quarter ended September 30, 2026.
  • R&D expenses were $25.2 million for the quarter ended September 30, 2026, compared to $18.1 million for the quarter ended September 30, 2025.
  • SG&A expenses were $93.9 million for the quarter ended September 30, 2026, compared to $83.6 million for the quarter ended September 30, 2025.
  • Long-term debt was $252,360 (in thousands) as of September 30, 2026.
  • Coverage and reimbursement decisions, including prior authorization and step-edit requirements, are identified as risks.

What to watch

  • Full-year 2026 IBSRELA revenue guidance of between $350 and $370 million.
  • Full-year 2026 XPHOZAH revenue guidance of between $110 and $120 million.
  • Full-year 2026 operating expense guidance below $500 million.
  • Topline data from the Phase 3 ACCEL trial in the second half of 2027.
  • U.S. Patent No. 12,788,750, expected to issue on November 10, 2026, with an expiration date of December 6, 2041.

Balance sheet and cash flow

  • Total cash, cash equivalents and short-term investments of $285.3 million as of September 30, 2026, compared to $264.7 million as of December 31, 2025.
  • Long-term debt was $252,360 (in thousands) as of September 30, 2026, compared to $202,834 (in thousands) as of December 31, 2025.
  • Inventory was $157,559 (in thousands) as of September 30, 2026, compared to $123,107 (in thousands) as of December 31, 2025.

Analysis

Ardelyx reported total product sales, net of $125.5 million in the third quarter, compared with $105.5 million in the prior-year quarter, reflecting 19% growth. IBSRELA generated $96.3 million and grew 23% year-over-year, with growth attributed to increases in total writers and total prescriptions. XPHOZAH generated $29.2 million and grew 7% year-over-year. Total revenues were $127,655 (in thousands), including product supply revenue, licensing revenue and non-cash royalty revenue related to the sale of future royalties.

The company recorded income from operations of $4,023 (in thousands), compared with $4,668 (in thousands) a year earlier, and net loss was $(737) (in thousands), compared with $(969) (in thousands). R&D expense rose to $25,199 (in thousands) from $18,067 (in thousands), primarily reflecting investments in the ACCEL Phase 3 trial for CIC. SG&A rose to $93,894 (in thousands) from $83,612 (in thousands), reflecting investment intended to address access barriers and drive future IBSRELA adoption. The quarter's net loss included share-based compensation expense of $15.1 million.

For the first nine months, total product sales, net were $336,957 (in thousands), compared with $263,406 (in thousands). Total revenues were $343,005 (in thousands), while total costs and operating expenses were $384,200 (in thousands). The nine-month net loss narrowed to $(55,063) (in thousands) from $(61,192) (in thousands), although R&D and SG&A were both higher than in the prior-year period.

Liquidity was $285.3 million in total cash, cash equivalents and short-term investments as of September 30, 2026, compared with $264.7 million as of December 31, 2025. The balance sheet also showed $252,360 (in thousands) of long-term debt, compared with $202,834 (in thousands) at December 31, 2025. Inventory was $157,559 (in thousands), compared with $123,107 (in thousands) at year-end.

Management reiterated full-year 2026 guidance for IBSRELA revenue between $350 and $370 million, XPHOZAH revenue between $110 and $120 million, and operating expenses below $500 million. The company also completed enrollment ahead of schedule in ACCEL and remains on track to announce topline data in the second half of 2027. The operating trajectory, commercial uptake for both products, spending against the access strategy and ACCEL execution are the central reported milestones.

Management, verbatim

Our third quarter results reflect the strength of the foundation we’ve built. IBSRELA year-over-year growth of 23% is the engine driving total product revenue of over $125 million for the quarter. With our robust tenapanor intellectual property portfolio, and our fully enrolled Phase 3 ACCEL trial for CIC, the value of IBSRELA continues to strengthen. Finally, with over $285 million in cash and investments, and a disciplined capital allocation strategy, we are well positioned to create and deliver significant long-term value.

Mike Raab, President and Chief Executive Officer of Ardelyx

Not in the filing

stated, not guessed
  • Gross margin was not reported.
  • Non-GAAP revenue, gross margin, operating income, net income and EPS were not reported.
  • Operating cash flow and free cash flow were not reported.
  • Share repurchases and dividends were not reported.
  • A prior earnings release outlook was not provided, so comparison with prior guidance is unavailable.
  • Quarter-over-quarter comparisons were not reported.
  • A tax rate was not reported.
  • Balance-sheet line items not individually included in key metrics: prepaid commercial manufacturing, property and equipment, right-of-use assets, prepaid and other assets, accounts payable, accrued compensation and benefits, current portion of operating lease liability, deferred revenue, accrued expenses and other liabilities, and total liabilities and stockholders’ equity.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about ARDX earnings dates

When is Ardelyx's next earnings date?
AlphAI has no date for ARDX yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.